Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
326.52B
Market cap326.52B
Price-Earnings ratio
140.71
Price-Earnings ratio140.71
Dividend yield
2.47%
Dividend yield2.47%
Average volume
7.69M
Average volume7.69M
High today
$139.17
High today$139.17
Low today
$132.45
Low today$132.45
Open price
$139.17
Open price$139.17
Volume
6.02M
Volume6.02M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$93.90
52 Week low$93.90

Stock Snapshot

With a market cap of 326.52B, Merck(MRK) trades at $132.45. The stock has a price-to-earnings ratio of 140.71 and currently yields dividends of 2.47%.

As of 2026-11-19, Merck(MRK) stock has fluctuated between $132.45 and $139.17. The current price stands at $132.45, placing the stock 0.0% above today's low and -4.8% off the high.

The Merck(MRK)'s current trading volume is 6.02M, compared to an average daily volume of 7.69M.

During the past year, Merck(MRK) stock moved between $93.90 at its lowest and $156.92 at its peak.

During the past year, Merck(MRK) stock moved between $93.90 at its lowest and $156.92 at its peak.

MRK News

TipRanks 4h
Halozyme provides update on German preliminary injunction hearing

Halozyme (HALO) provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck (MRK) to re...

Seeking Alpha 5h
Merck inks cancer research deal with AI drug discovery firm Isomorphic Labs

Merck (MRK) is joining hands with AI-driven drug discovery firm Isomorphic Labs to discover drug candidates against cancer, the companies announced on Thursday....

Merck inks cancer research deal with AI drug discovery firm Isomorphic Labs
TipRanks 6h
Merck and Isomorphic Labs to collaborate in drug discovery

Merck (MRK) and Isomorphic Labs, an AI-first drug design and development company, announced a research collaboration that brings together Isomorphic Labs’ AI ap...

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

TipRanks 21h
Merck Appoints Douglas Baker Jr. as Lead Director

Merck & Company ( (MRK) ) has provided an announcement. On Nov. 16, 2026, Thomas H. Glocer notified Merck of his intention to retire from its board at the May...

Benzinga 1d
Merck Pulls Plug On Acquired Drug after Safety Review

Merck & Co. Inc. (NYSE:MRK) on Tuesday announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational,...

Merck Pulls Plug On Acquired Drug after Safety Review
Zacks 1d
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

Merck (MRK Quick QuoteMRK - Free Report) has made considerable progress in advancing the pipeline, particularly in areas like oncology, vaccines and infec...

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
TipRanks 1d
Merck says Thomas Glocer to retire from board of directors

Merck (MRK) announced that Thomas Glocer intends to retire from the Merck Board of Directors at the company’s Annual Meeting of Shareholders in May 2027. The in...

Seeking Alpha 2d
Merck ends development of BTK inhibitor nemtabrutinib

Merck ends development of BTK inhibitor nemtabrutinib Nov 17, 2026, 5:05 PM ET Merck & Co., Inc. (MRK) Stock By : Jonathan Block, SA News Editor Merck ( MRK non...

Merck ends development of BTK inhibitor nemtabrutinib
TipRanks 2d
Merck announces discontinuation of development program evaluating MK-1026

Merck (MRK) announced the discontinuation of the clinical development program evaluating nemtabrutinib, an investigational, oral, non-covalent Bruton’s tyrosine...

Simply Wall St 2d
There May Be Some Bright Spots In Merck's Earnings

Merck & Co., Inc.'s ( ) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed strength. We think that investors might be loo...

There May Be Some Bright Spots In Merck's Earnings

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.